We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
COVID-19 and Parkinsonism: A Critical Appraisal.
- Authors
Cavallieri, Francesco; Fioravanti, Valentina; Bove, Francesco; Del Prete, Eleonora; Meoni, Sara; Grisanti, Sara; Zedde, Marialuisa; Pascarella, Rosario; Moro, Elena; Valzania, Franco
- Abstract
A few cases of parkinsonism linked to COVID-19 infection have been reported so far, raising the possibility of a post-viral parkinsonian syndrome. The objective of this review is to summarize the clinical, biological, and neuroimaging features of published cases describing COVID-19-related parkinsonism and to discuss the possible pathophysiological mechanisms. A comprehensive literature search was performed using NCBI's PubMed database and standardized search terms. Thirteen cases of COVID-19-related parkinsonism were included (7 males; mean age: 51 years ± 14.51, range 31–73). Patients were classified based on the possible mechanisms of post-COVID-19 parkinsonism: extensive inflammation or hypoxic brain injury within the context of encephalopathy (n = 5); unmasking of underlying still non-symptomatic Parkinson's Disease (PD) (n = 5), and structural and functional basal ganglia damage (n = 3). The various clinical scenarios show different outcomes and responses to dopaminergic treatment. Different mechanisms may play a role, including vascular damage, neuroinflammation, SARS-CoV-2 neuroinvasive potential, and the impact of SARS-CoV-2 on α-synuclein. Our results confirm that the appearance of parkinsonism during or immediately after COVID-19 infection represents a very rare event. Future long-term observational studies are needed to evaluate the possible role of SARS-CoV-2 infection as a trigger for the development of PD in the long term.
- Subjects
PARKINSONIAN disorders; PARKINSON'S disease; COVID-19; BASAL ganglia; ENCEPHALITIS
- Publication
Biomolecules (2218-273X), 2022, Vol 12, Issue 7, pN.PAG
- ISSN
2218-273X
- Publication type
Article
- DOI
10.3390/biom12070970